Morpholine derivates as inhibitors of Vps34

A compound of Formula I:

• wherein
• R1 is C6-C14 aryl, 5- to 10-membered heteroaryl, C3-C6 cycloalkyl, or 4- to 10-membered heterocycloalkyl, wherein the C6-C14 aryl, 5- to 10-membered heteroaryl, C3-C6 cycloalkyl, or 4- to 10-membered heterocycloalkyl of R1 are each unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, —CN, —NO2, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, C1-C6 haloalkyl, —ORa, —SRa, —S(O)2Ra, —NRbRc, —C(O)Ra, —OC(O)Ra, —C(O)ORa, —C(O)NRbRc, —OC(O)NRbRc, —NRaC(O)Rb, —NRaC(O)ORb, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C3-C6 cycloalkenyl, substituted or unsubstituted C6-C14 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, and substituted or unsubstituted 4- to 10-membered heterocycloalkyl;
• L is —S(O)2—, —O—, —C(O)— or CH2—;
• Y1 is CH or N;
• R2 is a 5-membered heteroaryl or a 5-membered heterocycloalkyl, wherein the 5-membered heteroaryl and 5-membered heterocycloalkyl of R2 are each unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, —CN, —NO2, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, C1-C6 haloalkyl, —ORd, —SRd, —S(O)2Rd, —NReRf, —C(O)Rd, —OC(O)Rd, —C(O)ORd, —C(O)NReRf, —OC(O)NReRf, —NRdC(O)Re, —NRdC(O)ORe, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C3-C6 cycloalkenyl, substituted or unsubstituted C6-C14 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, and substituted or unsubstituted 4- to 10-membered heterocycloalkyl;
• and
• Ra, Rb, Re, Rd, Re, and Rf are each independently H or C1-4 alkyl;
• wherein when L is —S(O)2— and Y1 is N, R1 is not 4,4-difluoro-piperidin1-yl;
• or a pharmaceutically acceptable salt thereof.